Canaccord raised the firm’s price target on Taysha Gene Therapies (TSHA) to $11 from $9 and keeps a Buy rating on the shares. The firm noted the company shared both a regulatory and a clinical update (longer term low-dose follow-up data and first look at high-dose data) for its TSHA-102 program for Rett Syndrome. Canaccord updated its model for the updates, namely increasing their assigned POS on TSHA-102 to 75% from 50% previously and the roughly $200M offering via a mix of shares and prefunded warrants.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Needham healthcare analyst holds analyst/industry conference call
- Taysha Gene Therapies price target raised to $8 from $6 at Needham
- Positive Outlook for Taysha Gene Therapies: Buy Rating on Promising TSHA-102 Advancements
- Positive Outlook for Taysha Gene Therapies: Strong Study Design and Promising Data Support Buy Rating
- Taysha Gene Therapies Announces Major Stock Offering